News

FS102 is being developed to treat breast and gastric cancer in HER2-positive patients who do not respond or become resistant to the existing therapies. HER2, a highly validated

The IND was based on a pivotal Phase III protocol for Neutrolin in hemodialysis patients with a central venous catheter. The multi-center, randomized, controlled Phase III clinical trial

Funded by the EU Innovative Medicines Initiative (IMI), the consortium aims to define a standard for the responsible use of dwindling reserves of effective antibiotics. The new consortium

Under the deal, LLR will provide access to new therapies currently being researched by its scientists, as well as offer financial support for Cancer Research UK to develop

MuGard is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. PlasmaTech Biopharmaceuticals

AKB-6548 is designed to stabilize hypoxia inducible factor (HIF), a transcription factor that regulates the expression of genes involved with red blood cell (RBC) production in response to

Fresenius Kabi is a global health care company that specializes in life-saving medicines and technologies for infusion, transfusion and clinical nutrition. Kabiven was approved by the U.S. Food

This finding is the culmination of more than 10 years of work by more than a dozen scientists and clinicians in the research team in Sarasota. Alzheimer’s has

The U.S. Food and Drug Administration (FDA) has approved Octagam10% for the treatment of adults with chronic Immune Thrombocytopenic Purpura (ITP), a platelet disorder that can result in